Our Partners

At the heart of Open Targets is a consortium of complementary partner institutions that bring their respective expertise to collaborative projects that improve how we systematically identify and prioritise drug targets.

News

A tumoroid, colon cancer cells grown in 3D

Cancer drug resistance causes and categories identified

18 October 2024

Researchers have mapped the genetic landscape of cancer drug resistance, uncovering that DNA changes can be grouped into four main categories and highlighting possible new therapeutic targets.


All cancer mutations that cause drug resistance fall into one of four categories. New research has detailed each type, helping to uncover targets for drug development and identify potential effective second-line therapies.

In a new large-scale study, re...

Read more

Read more news about Open Targets

Our Principles

A systematic approach

Systematically identify and prioritise the best targets to safely and effectively treat rare and common diseases

Our scientific approach
Open Exchange of Ideas

We are committed to making our data, methods and results publicly available as soon as possible to foster an open exchange of ideas

Our latest publications
Multidisciplinary collaboration

We believe in non-exclusive partnerships that foster the free exchange of ideas, expertise, and data

Our partners and collaborators

Blog

Bluesky